Gilead scores expanded label for hepatitis B drug Vemlidy in children 6 years and older
The FDA expanded the label for Gilead’s hepatitis B drug Vemlidy on Thursday to patients as young as 6 years old. Vemlidy, or tenofovir alafenamide, is a once-daily treatment for chronic hepatitis B that pulled in $862 million in sales for Gilead in 2023, up from $842 million in 2022.